Allogeneic hematopoietic stem-cell transplantation for hematological malignancies;Allogreffes de cellules souches hématopoïétiques dans le traitement des hémopathies malignes

Bulletin du Cancer

Volumn 88, Issue 9, 2001, Pages 908-926

  Michallet, M ^a   Dhedin, N ^a   Michallet, A S ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Allogeneic transplantation; Hematological malignancy; Hematopoietic stem cell

Indexed keywords

ACUTE LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGRAFT; CANCER SURVIVAL; CHRONIC LEUKEMIA; DENDRITIC CELL; ENDOCRINE DISEASE; ERADICATION THERAPY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; LYMPHOCYTE; REVIEW; TECHNIQUE; TREATMENT INDICATION; UMBILICAL CORD BLOOD; VEIN OCCLUSION;

BONE MARROW TRANSPLANTATION; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; INFECTION; LEUKEMIA; LYMPHOMA; NEOPLASMS, SECOND PRIMARY; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 18144443134     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (162)

1. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Société française de greffe de moelle
2. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution
3. High resolution HLA class I and II typing and CTLp frequency in unrelated donor transplantation: A single-institution retrospective study of 69 BMTs
4. Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: Implications for unrelated bone marrow donor selection
5. Single dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: A non-randomized comparative study of 54 patients at the Institut Gustave-Roussy
6. Interstitial pneumonitis following bone marrow transplantation after low dose rate total body irradiation
7. TBI regimens for marrow grafting
8. Interstitial pneumonitis and veno-occlusive disease of the liver after bone marrow transplantation
9. TBI technique and clinical results of leukemia patients at the university of Tübinger
10. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: Toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation
11. Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiarion in patients with hematologic malignancies
12. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens
13. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation
14. Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation
15. The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: A cooperative study of 62 patients
16. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission
17. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory, regimen for marrow transplantation in patients with advanced hematological malignancies: A phase I study
18. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide
19. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: A randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the French Society of Bone Marrow Graft (SFGM)
20. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen
21. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia
22. The impact of marrow transplant preparative regimens on subsequent growth and development
23. Stable mixed hematopoietic chimerism in DLA identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
24. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
25. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation
26. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
27. Adoptive immunotherapy evaluating doses of donor leukocytes for relapse of CML after bone marrow transplantation: Separation of GVL responses from GVHD
28. The biology of graft-versus-host reactions
29. Effect of TB1 busulfan-cyclophosphamide or cyclophosphamide conditioning on inflamatory cytokines release and development of a and c GVHD in H-2 incomparible transplanted SCID mice
30. Tumor necrosis factor combines with IL4 and IFNy to selectively enhance endothelial cell adhesiveness for T cells
31. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity, without severe GVHD
32. Cell surface molecules and early events involved in human T lymphocyte activation
33. GVH reactions in beige mouse: An investigation of role of host and donor natural killer cells in the pathogenesis of GVHD
34. Evidence that large granular lymphocytes of donor origin mediate aGVHD
35. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program
36. Risk factors for a GVHD in histocompatible donor bone marrow transplantation
37. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors
38. Methotrexate and ciclosporine compared with ciclosporine alone for prophylaxis of acute GVHD after marrow transplantation for leukemia
39. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: A prospective randomized study
40. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease
41. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study
42. Impact of T-cell depletion outcome of allogeneic bone marrow transplantation for standard risk leukemias
43. Successfull graft versus host disease prevention without graft failure in 32 HLA-identical allogeneic BMT depleted of T-cells by monoclonal antibodies and complement
44. Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome
45. Response of graft versus host disease to high doses of methyl prednisolone
46. Management of acute graft-versus-host disease
47. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: A randomized trial comparing antithymocyte globulin and corticosteroids
48. Mycophenolate mofetil for rhe treatment of acute and chronic GVHD in bone marrow transplant patients
49. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody: A multicenter phase III study
50. Specificity of effector T lymphocytes in autologous GVHD: Role of MHC complex classe 11 invariant chain
51. Chronic GVHD in 52 patients: Adverse natural course and successful treatment with combination immunosuppression
52. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
53. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
54. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease
55. Photoinactivation of lymphohemopoietic cells: Studies in transfusion medicine and bone marrow transplantation
56. Mixed blood chimerism in T-cell depleted BMT recipients: Evaluation using DNA polymorphisms
57. Characterization of cells emerging at the time of graft failure after bone marrow transplantation from an unrelated marrow donor
58. Hematopoietic engraftment and graft failure after bone marrow transplantation
59. Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning
60. Graft failure after T cell depleted HLA identical allogeneic bone marrow transplantation: Risk factors in leukemic patients
61. Successful engraftment of T-cell-depleted haploidentical « three-loci » incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum
62. Granulocyte colony-stimulating factor-mobilized allogeneic peripheral blood stem ceil for rescue graft failure after allogeneic bone marrow transplantation in two patients with acute myeloblastic leukemia in first complete remission
63. Treatment of graft failure after bone marrow transplantation
64. Graft-versus-leukemia: No longer an epiphenomenon
65. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
66. Adoptive immunotherapy in canine chimeras
67. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect
68. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18)
69. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
70. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
71. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors
72. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation
73. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation
74. T-cell immunity to the joining region of p210BCR-ABL protein
75. Antileukemic HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts
76. Febrile neutropenia in allogeneic transplantation
77. Towards a targeted, risk-based, antifungal strategy in neutropenic patients
78. Aspergillosis in bone marrow transplant recipients
79. T-cell regeneration after bone marrow transplantation: Differential CD45 isoform expression on thymic-derived versus thymic-independant progeny
80. T-cell regeneration: All repertoires are not created equal
81. + T-lymphocyte regeneration after intensive chemotherapy
82. Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: Two-color flow analysis
83. Viral infections with bone marrow transplantation
84. Advances in the control of cytomegalovirus disease in bone marrow transplant patients
85. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic bone marrow transplantation: A randomized double-blind study
86. Preemptive therapy of cytomegalovirus disease in pediatric transplant recipients
87. Human herpesvirus-6 in transplantation: An emerging pathogen
88. Human herpesvirus 6 infections after bone marrow transplantation: Clinical and virologic manifestations
89. Human herpesvirus 6 infection and associated pathogenesis following bone marrow transplantation
90. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management
91. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen
92. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: A retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc
93. Pneumocystis carinii pneumonia in patients without HIV infection
94. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts
95. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts
96. Restoration of viral immunity in immunodeficient humans by the adoptive transfer oft cell clones
97. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
98. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
99. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
100. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
101. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hematopoietic stem-cell transplantation
102. Malignancies after hematopoietic stem cell transplantation: Many questions, some answers
103. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study
104. Solid cancers after bone marrow transplantation
105. Non bacterial pneumoniae after allogenic BMT: A review of 10 years' experience
106. Idiopathic pneumonia syndrome: Changing spctrum of lung injury after marrow transplantation
107. Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: Value of gray-scale and Doppler US in 100 patients
108. The pathology, diagnosis, and treatment of hepatic reno-occlusive disease: Current status and novel approaches
109. Veno-occlusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms
110. A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission
111. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: Does it have clinical significance?
112. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia
113. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation
114. Ovarian function following marrow transplantation for aplastic anemia or leukemia
115. Ovarian function after autologous bone marrow transplantation in childhood: High-dose busulfan is a major cause of ovarian failure
116. Ovarian function after bone marrow transplantation performed before menarche
117. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
118. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation
119. Hematopoietic stem cell transplants from unrelated donors
120. Fractionated total body irradiation and high-dose etoposide as a preparatory, regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission
121. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: A retrospective study of 379 patients reported to the Société française de greffe de moelle (SFGM)
122. Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: An update
123. Allogeneic hematopoietic stem cell transplantation for acute leukemia
124. Adult acute lymphoblastic leukemia: A multicentric randomized trial testing bone marrow transplantation as postremission therapy
125. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia in first remission: A cooperative study of the Groupe d'étude de la greffe de moelle osseuse
126. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission
127. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): A series of 73 patients from the SFGM database
128. Allogeneic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival is worse because of higher treatment related mortality: A report of 764 cases from EBMT lymphoma registry
129. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
130. Allogeneic bone marrow transplantation in multiple myeloma
131. The Seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS)
132. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia
133. Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia
134. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: A survey of the Société française de greffe de moelle (SFGM)
135. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation
136. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
137. Effect of granulocyre colony-stimulating factor mobilization on phenotypical and function properties of immune cells
138. + stem cells: A new option for leukemia patients without an HLA-matched donor
139. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells
140. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
141. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells
142. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
143. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
144. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
145. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
146. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool
147. Transplantation of anergic histoincompatible bone marrow allografts
148. Selective removal of alloreactive cells from haematopoietic stem cell grafts: Graft engineering for GVHD prophylaxis
149. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity
150. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft
151. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: Results of a marched-pair analysis
152. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia
153. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling
154. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation
155. Outcomes among 562 recipients of placental-blood transplants from unrelated donors
156. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: Analysis of engraftment and acute graft-versus-host disease
157. Placental blood as a source of hematopoletic stem cells for transplantation into unrelated recipients
158. Outcome of cord-blood transplantation from related and unrelated donors
159. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation
160. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer
161. Hematopoietic cell culture therapies (Part II): Clinical aspects and applications
162. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismarched HLA haplotype